Pazinib 200 mg contains Pazopanib, a multi-targeted tyrosine kinase inhibitor (TKI) that blocks key receptors responsible for tumor cell proliferation and blood vessel formation. It is widely used in oncology for managing advanced solid tumors.

🔬 Mechanism of Action

Pazopanib inhibits several receptor tyrosine kinases, including:

• VEGFR (Vascular Endothelial Growth Factor Receptors)
• PDGFR (Platelet-Derived Growth Factor Receptors)
• c-KIT

By targeting these pathways, Pazopanib reduces angiogenesis (formation of new blood vessels) and limits tumor growth and spread.

💊 Indications

Pazinib 200 mg is indicated for:

• Advanced Renal Cell Carcinoma (RCC)
• Advanced Soft Tissue Sarcoma (STS) after prior chemotherapy

📌 Key Features of Pazinib 200 mg

• Strength: 200 mg
• Dosage Form: Oral tablet
• Therapeutic Class: Multi-targeted Tyrosine Kinase Inhibitor
• Administration: Typically 800 mg once daily (4 tablets of 200 mg) taken on an empty stomach
• Monitoring: Liver function tests, blood pressure, thyroid function, and cardiac monitoring required

⚕️ Benefits of Pazopanib

• Effective targeted therapy for advanced cancers
• Oral administration for convenience
• Reduces tumor vascularization
• Helps delay disease progression

⚠️ Precautions

• Risk of hepatotoxicity — regular liver function monitoring required
• May cause hypertension, diarrhea, fatigue, and hair color changes
• Risk of QT prolongation and cardiac dysfunction
• Dose adjustments may be necessary based on tolerance
• Use strictly under oncologist supervision

Pazinib 200 mg (Pazopanib Tablets) provides an effective targeted treatment option for advanced renal cell carcinoma and soft tissue sarcoma, supporting improved disease control when administered under specialized oncology care.